Oztas, 650 patient HCQ prophylaxis study: 215% higher hospitalization [p=0.36], 40% more symptomatic cases [p=0.44], and 5% more cases [p=0.88] https://c19p.org/oztas
copied to clipboard
Frequency and Severity of COVID-19 in Patients with Various Rheumatic Diseases Treated Regularly with Colchicine or Hydroxychloroquine
et al., Journal of Medical Virology, doi:10.1002/jmv.27731
Retrospective 317 HCQ users and 333 household contacts, showing higher risk with HCQ.Authors do not adjust for the very different baseline risk for systemic
autoimmune disease patients. Other research shows that the risk of COVID-19
for systemic autoimmune disease patients is much higher overall, Ferri et al.
show OR 4.42, p<0.001 [Ferri].
|
risk of hospitalization, 215.1% higher, RR 3.15, p = 0.36, treatment 3 of 317 (0.9%), control 1 of 333 (0.3%).
|
|
risk of symptomatic case, 40.1% higher, RR 1.40, p = 0.44, treatment 16 of 317 (5.0%), control 12 of 333 (3.6%).
|
|
risk of case, 5.0% higher, RR 1.05, p = 0.88, treatment 22 of 317 (6.9%), control 22 of 333 (6.6%).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
not adjusting for the different baseline risk of systemic autoimmune patients, excessive unadjusted differences between groups.
Oztas et al., 21 Mar 2022, retrospective, Turkey, peer-reviewed, 15 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.